{ "@type": "Dataset", "name": "@Medidata on X", "description": "Followers, posts and engagement for @Medidata.", "url": "https://tweetindex.com/account/Medidata", "isAccessibleForFree": true, "creator": { "@id": "https://tweetindex.com/#organization" }, "variableMeasured": [ { "@type": "PropertyValue", "name": "Followers", "value": 11483 }, { "@type": "PropertyValue", "name": "Following", "value": 4710 }, { "@type": "PropertyValue", "name": "Posts", "value": 25325 }, { "@type": "PropertyValue", "name": "Collected posts", "value": 5 }, { "@type": "PropertyValue", "name": "Views on collected posts", "value": 511 }, { "@type": "PropertyValue", "name": "Likes on collected posts", "value": 4 } ], "distribution": [ { "@type": "DataDownload", "contentUrl": "https://tweetindex.com/api/accounts/Medidata", "encodingFormat": "application/json" } ], "@id": "https://tweetindex.com/account/Medidata#dataset" }

Medidata ✓

@Medidata · New York, NY · joined 15 Mar 2009

Powering the future of clinical development with unrivaled AI, deep data science, and end-to-end expertise. 🧬🔬🧪 🏠 Part of @Dassault3DS

11 483Followers

4 710Following

25 325Posts total

511Views on collected posts

Latest posts

Medidata ✓@Medidata16 Sep

Data silos are a constant bottleneck for clinical trial sites. They cause researchers to lose sight of critical signals like eCOA (electronic clinical outcome assessment) completion, sensor information, and consent status, leading disengaged patients to fall through the cracks ht

13 views · 0 likes · 0 reposts · 0 replies Open on X →

Medidata ✓@Medidata11 Sep

Every clinical trial starts with a single protocol, yet getting to a final digital study build remains a fragmented, heavily manual process. Thanks to AI, it doesn’t have to be. Joe Lovett’s session “How to Use AI to Dramatically Accelerate Study Build and Deliver a Unified Data

125 views · 1 likes · 0 reposts · 0 replies Open on X →

Medidata ✓@Medidata11 Sep

Study build doesn't have to be slow, manual, or frustrating. Dare we say it can even be fun? Marco Amorim’s new video series Cracking the Study Build Code shares practical ways AI is helping research teams simplify clinical trial design, eliminate repetitive tasks, and focus on

0:29

106 views · 0 likes · 0 reposts · 0 replies Open on X →

Medidata ✓@Medidata8 Sep

Research is a collaborative effort. We're proud to partner with the best in the business to deliver life-saving outcomes for patients. 🤝 @WeAreCaidya and Medidata have teamed up to drive a new generation of AI-powered studies and a unified clinical trial experience for everyone

130 views · 3 likes · 0 reposts · 0 replies Open on X →

Medidata ✓@Medidata7 Sep

Over 300 million people worldwide live with a rare disease. Roughly 0.1% of them suffer from Duchenne muscular dystrophy (DMD), a debilitating genetic disorder that worsens over time. This World Duchenne Awareness Day, we're proud to recognize visionaries like @EveryCure’s https

$\"Us humans have developed about 4,000 drugs for about 4,000 diseases, but there are 14,000 more diseases with no treatment.\" \u2013 David Fajgenbaum$

137 views · 0 likes · 0 reposts · 0 replies Open on X →

Against accounts of the same size

5 posts from the last 90 days, next to the 10K–100K follower range. reaches fewer people than peers of the same size.

Median views125this account924median for 10K–100K

Reach, %1.09%this account3.62%median for 10K–100K

Engagement, %0.00%this account1.52%median for 10K–100K

Metric	This account	Median for 10K–100K	Ratio
Median views per post	125	924	0.14×
Reach (views ÷ followers)	1.09%	3.62%	0.30×
Engagement rate	0.00%	1.52%	0.00×

Others in this range → Compare with another account → How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.